My reseach interests focus on appling mass-spectrometry based proteomics and proteogenomics to understand human proteome variation in health and diseases, and to identify new biomarkers. Particularly I focus on steatohepatitis and liver fibrosis, which are two key events on the spectrum of liver disease progression. Among the efforts, we established a cell-type resolved dymanic human liver proteome atlas, which we made into a publicly available resource for research on both basic liver physiology and pathology (www.liverproteome.org). Towards establishing non-invasive diagnostic methods for liver disease, we recently identified three biomarker panels for the early detection of key pathological features of liver disease, which we plan to follow up in even larger cohorts. In an ongoing population-based study, we aim to identify protein profiles in the plasma that indicate metabolic risks, such as obesity and fatty liver.